First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Autor: Shaw, A. T., Bauer, T. M., De Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. -W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., Solomon, B. J., Soto Parra, H.

Publikováno v: CROWN Trial Investigators & Blackhall, F 2020, ' First-line lorlatinib or crizotinib in advanced alk-positive lung cancer ', New England Journal Of Medicine, vol. 383, no. 21, pp. 2018-2029 . https://doi.org/10.1056/NEJMoa2027187

BACKGROUND: Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e198e069fced42b320415b72e5031c98
https://doi.org/10.1056/nejmoa2027187